DE602004022176D1 - Multisystem-therapie für diabetes, das metabolische syndrom und adipositas mit einem hypoglykämischen mittel - Google Patents

Multisystem-therapie für diabetes, das metabolische syndrom und adipositas mit einem hypoglykämischen mittel

Info

Publication number
DE602004022176D1
DE602004022176D1 DE602004022176T DE602004022176T DE602004022176D1 DE 602004022176 D1 DE602004022176 D1 DE 602004022176D1 DE 602004022176 T DE602004022176 T DE 602004022176T DE 602004022176 T DE602004022176 T DE 602004022176T DE 602004022176 D1 DE602004022176 D1 DE 602004022176D1
Authority
DE
Germany
Prior art keywords
hypoglykemic
adipositas
multisystem
diabetes
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022176T
Other languages
English (en)
Inventor
Franco Folli
Paolo Manfredi
Gilbert Gonzales
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOLLI, FRANCO, SAN ANTONIO, TEX., US
Gonzales Gilbert New York Ny Us
Manfredi Paolo New York Ny Us
Original Assignee
FOLLI FRANCO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOLLI FRANCO filed Critical FOLLI FRANCO
Publication of DE602004022176D1 publication Critical patent/DE602004022176D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004022176T 2003-09-08 2004-08-26 Multisystem-therapie für diabetes, das metabolische syndrom und adipositas mit einem hypoglykämischen mittel Active DE602004022176D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50122603P 2003-09-08 2003-09-08
US10/868,227 US20050054731A1 (en) 2003-09-08 2004-06-15 Multi-system therapy for diabetes, the metabolic syndrome and obesity
PCT/US2004/027689 WO2005025673A1 (en) 2003-09-08 2004-08-26 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent

Publications (1)

Publication Number Publication Date
DE602004022176D1 true DE602004022176D1 (de) 2009-09-03

Family

ID=34228829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022176T Active DE602004022176D1 (de) 2003-09-08 2004-08-26 Multisystem-therapie für diabetes, das metabolische syndrom und adipositas mit einem hypoglykämischen mittel

Country Status (7)

Country Link
US (1) US20050054731A1 (de)
EP (1) EP1663395B1 (de)
CA (1) CA2538333A1 (de)
DE (1) DE602004022176D1 (de)
ES (1) ES2328821T3 (de)
IL (1) IL174033A0 (de)
WO (1) WO2005025673A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
AU2005259864A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060035864A1 (en) * 2004-08-10 2006-02-16 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
US20060275249A1 (en) * 2005-06-03 2006-12-07 Jones Michael R Co-therapy for diabetic conditions
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CN1939540B (zh) * 2005-10-01 2011-07-06 安徽省现代中药研究中心 含有胰岛素增敏剂和b族维生素的药物组合物
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
WO2007131930A1 (en) * 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
BRPI0806774A2 (pt) * 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
CN101347434B (zh) * 2007-08-07 2012-01-04 北京奥萨医药研究中心有限公司 含有肾素抑制剂与叶酸类化合物的药物组合物及其用途
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
CN101590240B (zh) * 2008-05-30 2012-04-25 北京奥萨医药研究中心有限公司 含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
WO2010028211A1 (en) * 2008-09-04 2010-03-11 Rozmanith Anthony I Health care
ES2690741T3 (es) * 2009-02-11 2018-11-22 Cadila Pharmaceuticals Ltd. Composición farmacéutica estable para la aterosclerosis
EP2408434A4 (de) * 2009-03-16 2013-11-27 Ipintl Llc Behandlung von morbus alzheiner und osteoporose sowie reduzierung von alterung
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
US20140155349A1 (en) * 2010-01-28 2014-06-05 Anthony I. Rozmanith Health Care
NZ701274A (en) * 2010-02-24 2016-03-31 Emisphere Tech Inc Oral b12 therapy
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
DE212011100215U1 (de) * 2011-07-22 2014-03-05 Karel Paul Bouter Ernährungsprodukt, umfassend ein Biguanid
US20150133397A1 (en) * 2013-08-15 2015-05-14 Jeffrey Lynn Barringer Method of reducing fasting insulin levels in mthfr gene deficient subjects with normal to slightly elevated hemoglobin a1c
CN106880644A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种由考来维仑制成的用于治疗获得性肥胖的药物组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
DE69325904T2 (de) * 1992-05-15 1999-12-09 Merrell Pharma Inc MERCAPTOACETYLAMIDE VON PYRIDAZO[1,2-a][1,2]-DIAZEPIN -DERIVATEN ALS EUKEPHALINASE UND ACE-INHIBITOREN
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
WO1998008546A2 (en) * 1996-08-28 1998-03-05 Institut National De La Sante Et De La Recherche Medicale Therapeutic combinations of rar antagonists and rxr agonists and use thereof
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
EP0965278A1 (de) * 1998-06-16 1999-12-22 Mathias Christian Zohoungbogbo Diätetisches Lebensmittel und diätetisches Verfahren unter Verwendung des Lebensmittels
AU750122C (en) * 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CA2376029A1 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
YU8803A (sh) * 2000-08-07 2006-01-16 Ranbaxy Signature L.L.C. Tečni oblik metformina
PE20020453A1 (es) * 2000-09-27 2002-06-06 Merck & Co Inc Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
HUP0300990A2 (hu) * 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére

Also Published As

Publication number Publication date
ES2328821T3 (es) 2009-11-18
WO2005025673A1 (en) 2005-03-24
EP1663395A1 (de) 2006-06-07
EP1663395B1 (de) 2009-07-22
IL174033A0 (en) 2006-08-01
CA2538333A1 (en) 2005-03-24
US20050054731A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
DE602004022176D1 (de) Multisystem-therapie für diabetes, das metabolische syndrom und adipositas mit einem hypoglykämischen mittel
NO20052516D0 (no) Fremgangsmate for a behandle insulinresistens, diabetes som inntrer i voksen alder og metabolsk syndrom X
CY2023026I1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
IL186592A0 (en) Treatment and diagnostic catheters with hydrogel electrodes
DK1781657T3 (da) Medikamenter med hm74a-receptor aktivitet
DK3542869T3 (da) Engangssøvn- og åndedrætsmonitor
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
DE602004020535D1 (de) Befestigungselement für das Verbinden und Beabstanden von Bauteilen
DE602005013322D1 (de) RAID mit Hochleistungs- und Niedrigleistungsplattenspieler
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
WO2006008779A8 (en) Use of hmgb1 for wound healing
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
NL2000135A1 (nl) Patientligtafel en computertomografie-apparaat dat een patientligtafel omvat.
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
EP2198054A4 (de) Verwendung von ccr9, ccl25/teck und integrin-alpha4 bei der diagnose und behandlung von melanommetastasierung im dünndarm
EP1901701A4 (de) Körperpflege- und medizinische produkte mit gebundenen schwefelorganischen gruppen
ATE496890T1 (de) Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen
EP1757303A4 (de) Arzneimittel mit humanem lysozym, dessen herstellungsverfahren und anwendung
EP1709991A4 (de) Elektrode zur behandlung und behandlungsvorrichtung
DE602004015763D1 (de) Herzschrittmacher mit verbesserter fähigkeit für das ermitteln des angriffes von tachyarrhythmias und von herzversagen
FR2870539B1 (fr) Nouvelles methodes et medicaments
ZA200710146B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
AU2003243427A8 (en) Methods of diagnosing and treating diabetes and insulin resistance

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GONZALES, GILBERT, NEW YORK, N.Y., US

Owner name: MANFREDI, PAOLO, NEW YORK, N.Y., US

Owner name: FOLLI, FRANCO, SAN ANTONIO, TEX., US

8364 No opposition during term of opposition